Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAXBiotechnology
+$0.00 today
- Market cap
- $622.71M
- Beta
- -0.53
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$2.59
Volume 1.30M
Average 0.54M
BCAX Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Bicara Therapeutics Inc. Common StockNASDAQ: BCAX
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity rises 12.0% from a year ago
Total equity stood at $513.96M at the end of Q1 FY2026, up 12.0% from a year earlier and up 28.0% from the prior quarter.
Context
- Total equity amounted to 92.8% of total assets at the end of Q1 FY2026, down 3.2 pp from a year earlier.
- Total equity increased in 2 of the last 3 fiscal years.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +12.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 401.45M USD
- Year-over-year change
- -18.4%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 401.45M | -18.4% |
| FY2024 | 2024-12-31 | 491.88M | +125.1% |
| FY2023 | 2023-12-31 | 218.51M | +1364.7% |
| FY2022 | 2022-12-31 | (17.28M) | — |
Total Equity vs competitors
How BCAX compares with its peers on the latest reported figures
- BCAX's Mar 2026 total equity of $513.96M is the highest of the 6 companies compared; the peer median is $183.85M.
- Its year-over-year change of +12.0% is the 3rd highest of 6, against a peer median of -33.6%.
- Total equity amounts to 92.8% of total assets for BCAX, versus a peer median of 90.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
BCAXBicara Therapeutics Inc. Common Stock | Mar 2026 | $513.96M | +12.0% | — | 92.8% |
| Mar 2026 | $366.17M | -33.6% | -8.6% | 90.9% | |
| Mar 2026 | $186.47M | +69.1% | +2.7% | 90.9% | |
| Mar 2026 | $183.85M | +5346.9% | +67.8% | 92.3% | |
| Mar 2026 | $52.2M | -42.6% | +20.3% | 88.7% | |
| Mar 2026 | $21.2M | -73.2% | -26.8% | 9.7% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding BCAX) | $183.85M | -33.6% | +2.7% | 90.9% | |
Competitors are the stored peer set for BCAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
Intrinsic Alpha fair value
Locked
Current Price
$9.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.